Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Safety and Activity of HF50 in Patients With Advanced Solid Tumors

23. september 2026 oppdatert av: HighField Biopharmaceuticals Corporation

A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of HF50 in Patients With Advanced Solid Tumors

A study to assess the safety, tolerability, and pharmacokinetics of HF50 in participants with advanced solid tumors.

Studieoversikt

Status

Rekruttering

Intervensjon / Behandling

Detaljert beskrivelse

This is an open-label, dose-escalation and dose-expansion, multiple-dose, phase 1 study evaluating HF50 monotherapy in participants with advanced solid tumors. HF50 is an innovative liposome-encapsulated T-cell engager designed to redirect T-cells to tumor cells by presenting both tumor-associated antigen (e.g., HER2) and CD3 targeting moieties on the liposome surface. Simultaneously, HF50 delivers an encapsulated TLR7/8 agonist to activate innate immunity and remodel the tumor immune microenvironment, creating a synergistic anti-tumor immune response.The primary objective is to evaluate the safety and tolerability of HF50 and to determine the recommended Phase 2 dose (RP2D). HF50 will be administered as an intravenous (IV) infusion. The study will also assess the pharmacokinetic (PK) profile, immunogenicity, and preliminary anti-tumor activity of HF50. Additionally, the study will explore the impact of HF50 on the immune microenvironment and changes in peripheral blood cytokines and immune cells to better understand its biological effects.

Studietype

Intervensjonell

Registrering (Antatt)

45

Fase

  • Fase 1

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

    • Beijing Municipality
      • Beijing, Beijing Municipality, Kina, 100021
        • Har ikke rekruttert ennå
        • Cancer Hospital, Chinese Academy of Medical Sciences
        • Ta kontakt med:
          • FEI MA, MD,PhD
        • Hovedetterforsker:
          • FEI MA, MD,PhD
    • Guangdong
      • Guangzhou, Guangdong, Kina, 510120
        • Rekruttering
        • Sun Yat-sen Memorial Hospital, Sun Yat-sen University
        • Hovedetterforsker:
          • Jing Li, MD, PhD
        • Hovedetterforsker:
          • Qiong Yang, MD, PhD
        • Ta kontakt med:
        • Hovedetterforsker:
          • HERUI YAO, MD,PhD

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Voluntary participation: Capable of giving signed informed consent and able to comply with all study-related procedures.
  • Age: Adults >= 18 years of age at the time of signing informed consent; male or female.
  • Disease Status: Participants with histologically or cytologically confirmed advanced solid tumors that are unresectable or metastatic, who have failed or are intolerant to standard therapies, or for whom no effective therapy currently exists. Examples include HER2-expressing gynecological tumors and recurrent ovarian clear cell carcinoma after failure of platinum-based chemotherapy.
  • Performance Status: Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 1.
  • Life Expectancy: Anticipated survival of no less than 6 months.
  • Measurable Disease: At least one measurable lesion according to RECIST v1.1 definitions.
  • Organ and Bone Marrow Function:

Bone Marrow Reserve: Absolute neutrophil count (ANC) >= 1.5 x 10^9/L, lymphocyte count >= 1.0 x 10^9/L, platelet count >= 90 x 10^9/L, and hemoglobin >= 9.0 g/dL (no blood transfusion or hematopoietic stimulators within 14 days).

Coagulation Function: Activated partial thromboplastin time (APTT) <= 1.5 x ULN, and International Normalized Ratio (INR) <= 1.5.

Liver Function: Total bilirubin (TBIL) <= 1.5 x ULN, and ALT and AST <= 2.5 x ULN. For participants with liver metastases: ALT and AST <= 5 x ULN, and TBIL <= 3 x ULN.

Renal Function: Creatinine clearance >= 50 mL/min (calculated using the Cockcroft-Gault formula).

  • Contraception: Participants of reproductive potential (including males) must agree to use effective contraception from study entry through 6 months after the last dose. Female participants of childbearing potential must have a negative serum pregnancy test during screening and prior to the first dose.

Exclusion Criteria:

  • Autoimmune Disease: Any active autoimmune disease or history of autoimmune disease deemed unsuitable by the investigator. Exceptions include skin conditions not requiring systemic treatment (e.g., eczema < 10% of body surface area, vitiligo, psoriasis, alopecia) and resolved childhood asthma.
  • Corticosteroids/Immunosuppressants: Current use of immunosuppressants or systemic corticosteroids (> 10 mg/day prednisone or equivalent) within 4 weeks prior to the first dose. Topical steroid use is permitted.
  • Prior Anti-tumor Therapy: Receipt of systemic chemotherapy, radiotherapy, targeted therapy, or immunotherapy within 2 weeks prior to dosing (4 weeks for nitrosoureas or mitomycin C); or other therapies (endocrine therapy, TCM, localized palliative radiotherapy) within 2 weeks.
  • CNS Metastasis: Clinically symptomatic brain or meningeal metastases. Participants with treated brain metastases are eligible if radiographic stability is maintained for >= 28 days, systemic steroids have been discontinued for > 14 days, and the participant is asymptomatic.
  • Toxicity Recovery: Failure to recover from all adverse events of prior therapies to <= Grade 1 (NCI CTCAE v5.0) or baseline, except for alopecia, Grade 2 peripheral neuropathy, or stable hypothyroidism on hormone replacement.
  • Cardiovascular History: Including thromboembolic events within 3 months; NYHA Class III to IV congestive heart failure; acute coronary syndrome, aortic dissection, stroke, or other Grade >= 3 cardiovascular events within 6 months; or uncontrolled hypertension (SBP > 160 mmHg or DBP > 100 mmHg).
  • Infection: Active infection or unexplained fever > 38.5 degrees C within 1 week prior to the first dose (tumor-related fever is permitted per investigator judgment).
  • Viral Infection: HIV infection, active HBV (HBV DNA > ULN), or active HCV (HCV RNA > ULN).
  • Gastrointestinal Symptoms: Significant digestive system symptoms or other factors requiring intervention within 4 weeks prior to the first dose.
  • Pregnancy/Lactation: Female participants who are pregnant or breastfeeding.
  • Other: Any other serious systemic disease or reason that, in the investigator's opinion, makes the participant unsuitable for the study.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: N/A
  • Intervensjonsmodell: Enkeltgruppeoppdrag
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: HF50

HF50 monotherapy

HF50 is an innovative liposome-encapsulated bifunctional therapeutic designed to redirect T-cells to HER2-expressing tumor cells while simultaneously activating innate immunity through TLR7/8 agonism.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Number of Participants with Dose Limiting Toxicities (DLT)
Tidsramme: 28 days after the first dose (C1D1) for each dose cohort.

The number of participants experiencing dose-limiting toxicities (DLTs) during the DLT evaluation period to determine the maximum tolerated dose (MTD).

28 days after the first dose (C1D1) for each dose cohort.
Incidence of Adverse Events (AEs)
Tidsramme: From first dose to 28 days after the last dose.

The number and percentage of participants experiencing adverse events (AEs), graded according to NCI-CTCAE v5.0

From first dose to 28 days after the last dose.
Recommended Phase II Dose (RP2D) of HF50
Tidsramme: At the end of dose escalation (assessed up to 1 year)

RP2D will be determined based on safety, tolerability, and pharmacokinetics data collected during the dose escalation phase.

At the end of dose escalation (assessed up to 1 year)

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Objective Response Rate (ORR)
Tidsramme: Up to 2 years

Proportion of participants achieving a complete response (CR) or partial response (PR) based on RECIST v1.1 criteria.

Up to 2 years
Duration of Response (DOR)
Tidsramme: Up to 2 years

Time from the first documented response (CR or PR) to disease progression or death.

Up to 2 years
Disease Control Rate (DCR)
Tidsramme: Up to 2 years

Proportion of participants achieving CR, PR, or stable disease (SD) based on RECIST v1.1.

Up to 2 years
Progression-Free Survival (PFS)
Tidsramme: Up to 2 years

Time from the first dose to disease progression or death.

Up to 2 years
Overall Survival (OS)
Tidsramme: Up to 2 years

Time from the first dose to death from any cause.

Up to 2 years
Pharmacokinetic Parameter - Cmax
Tidsramme: Up to 2 years

Maximum plasma concentration (Cmax) of HF50 will be assessed following single and multiple dosing.

Up to 2 years
Pharmacokinetic Parameter - Tmax
Tidsramme: Up to 2 years

Time to maximum plasma concentration (Tmax) of HF50 will be assessed following single and multiple dosing.

Up to 2 years
Pharmacokinetic Parameter - AUC (Area Under the Curve)
Tidsramme: Up to 2 years

AUC0-t and AUC0-inf will be evaluated to determine systemic exposure to HF50.

Up to 2 years
Pharmacokinetic Parameter - Half-life (t1/2)
Tidsramme: Up to 2 years

The terminal elimination half-life (t1/2) of HF50 will be calculated.

Up to 2 years

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Hovedetterforsker: HERUI YAO, MD,PhD, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

8. september 2026

Primær fullføring (Antatt)

30. juni 2028

Studiet fullført (Antatt)

30. juni 2029

Datoer for studieregistrering

Først innsendt

15. mai 2026

Først innsendt som oppfylte QC-kriteriene

15. mai 2026

Først lagt ut (Faktiske)

22. mai 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

28. september 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

23. september 2026

Sist bekreftet

1. mai 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • HF50-102

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

produkt produsert i og eksportert fra USA

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere